Use of shiva guggulu and baluka swedan in management of rheumatoid arthritis in children

Clinical Study Of Shiva Guggulu And Baluka Swedana In The Management Of Aamvata (Rheumatoid Arthritis) In Children.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/05/033414

Enrollment

Registered

2021-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M089- Juvenile arthritis, unspecified

Interventions

Intervention1: Shiva Guggulu: Shiva Guggulu Dose- Age of the child- 7-9 years-200 mg BD, 10-12 years- 250 mg BD, 13-16 years- 275 mg BD, The dose

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children having age of 7 to 16 years of either sex will be selected for study. 2. Children having sign and symptoms of Aamvata. 3. Pre-diagnosed and confirmed cases of Aamvata will be considered in study.

Exclusion criteria

Exclusion criteria: 1. Children having age below 7 years and above 16 years will be excluded from study. 2. Children having congenital deformities will be excluded from study. 3. Children suffering from any chronic illness just as Psoriatic Arthritis, Septic Arthritis, metabolic disorder like Diabetes Mellitus, liver diseases etc. will be exclude from study.

Design outcomes

Primary

Measure	Time frame
Relief in signs symptomsTimepoint: 45 days	—

Secondary

Measure	Time frame
Improvement in health statusTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Sonam Boyal

Dr Sarvepalli Radhakrishnan Rajsthan Ayurved University, Karwar, Jodhpur, Rajasthan

drppvyas@gmail.com9660057022

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026